The current approach, which initiates medications and escalates to mechanical circulatory support, has not resulted in a ...

Hospitals with a higher volume of percutaneous microaxial ventricular assist device implantation in the US have fewer deaths among cardiogenic shock patients.

Laboratories Inc., the biotechnology firm's stock (NASDAQ: WINT) has recorded a new 52-week low, dipping to $0.21. According ...

Background Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality.

Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating ...

Etiometry, the leader in clinical decision support software for high-acuity units, celebrates a year of groundbreaking achievements in 2024 and shares its ambitious vision to transform critical care ...

Most of the change in stage of cardiogenic shock (CS) occurred within the first 24 hours of presentation, with little change thereafter, according to a study by the Cardiogenic Shock Working Group ...

One long-awaited trial stood out: DanGer Shock (DANGER; 22 Across). In the 360-patient study, use of mechanical circulatory support with the Impella CP (Abiomed) microaxial flow pump lowered the risk ...

("Windtree” or the "Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that ...

Figure. Suggested approach to randomized clinical trial design, data acquisition, analysis, and results reporting for patients with cardiogenic shock, including patients with cardiac arrest (CA). CPC ...